<DOC>
	<DOC>NCT00781599</DOC>
	<brief_summary>Little is known about the support needed to improve compliance with Chantix for smoking cessation. This is a two arm pilot study of African American smokers to provide varying levels of side effect management and compliance support during a 12 week treatment period. The primary aim of the study is to estimate the effect of induction support compared to standard care in increasing compliance with Chantix at month 3</brief_summary>
	<brief_title>Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers</brief_title>
	<detailed_description />
	<mesh_term>Varenicline</mesh_term>
	<criteria>African American 1875 years of age Smoke more than 10 cigarettes per day Have a functioning telephone number Be interested in quitting smoking Be willing to take 3 months of Chantix Be willing to complete all study visits Renal impairment Evidence or history of clinically significant allergic reactions to Chantix Cardiovascular event in the past month History of alcohol or drug abuse/dependency in the past year Major depressive disorder in the last year requiring treatment History of panic disorder Psychosis, bipolar or eating disorder Use of antidepressants, antipsychotics, mood stabilizers/anticonvulsants or naltrexone Use of tobacco products other than cigarettes Use of nicotine replacement therapy, bupropion, clonidine or nortriptyline in the month prior to enrollment Prior use of Chantix Women who are pregnant, contemplating getting pregnant or breastfeeding Plans to move from Kansas City during the 3 month treatment phase Another household member enrolled in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>African american</keyword>
	<keyword>smokers</keyword>
	<keyword>smoking cessation</keyword>
	<keyword>African American smokers</keyword>
</DOC>